» Articles » PMID: 17846233

The Spectrum of Canine Cutaneous Perivascular Wall Tumors: Morphologic, Phenotypic and Clinical Characterization

Overview
Journal Vet Pathol
Date 2007 Sep 12
PMID 17846233
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Perivascular wall tumors (PWTs) are defined as neoplasms deriving from mural cells of blood vessels, excluding the endothelial lining. The spectrum of human cutaneous PWT includes glomus tumor, hemangiopericytoma (HEP), myopericytoma, angioleiomyoma/sarcoma, angiomyofibroblastoma, and angiofibroma. The purpose of this study was to revise clinical presentation, cytology, histopathology, and immunohistology of canine cutaneous PWT with cytology typical of canine HEP. Diagnosis was established on the basis of vascular growth patterns (staghorn, placentoid, perivascular whorling, bundles from media) and immunohistology, including 7 smooth muscle markers and the cell membrane ganglioside of unknown origin recognized by the antibody 3G5 (CMG-3G5). Twenty cases were included. Ages ranged from 6 to 13 years; 12 dogs were males and 8 were females, and there was a prevalence of crossbreeds. Tumors arose from a single site with preferential acral location (10/20). Cytology revealed moderate to high cellularity in all cases, cohesive groups of cells (19/20), capillaries (18/20), and bi- to multinucleated cells (18/20). Six myopericytomas, 5 angioleiomyomas, 2 angioleiomyosarcomas, 2 HEP, 1 angiofibroma, and 1 adventitial tumor were identified. A definitive diagnosis was not possible in 3 cases. Smoothelin, heavy caldesmon, desmin, myosin, calponin, and CMG-3G5 were the most valuable markers to differentially diagnose canine PWT. Similar to reports in humans, canine HEP embodied a spectrum of neoplastic entities arising from different vascular mural cells. Before canine PWTs are assimilated into one prognostic category, a consistent classification and characterization of their biology is necessary. As proposed in humans, HEP should also be considered a diagnosis of exclusion in dogs.

Citing Articles

Spontaneous histiocytic sarcoma originating from the epididymis in a CD-1 mouse.

Shimazaki T, Yasui Y, Anagawa-Nakamura A, Toyoda K, Yamazaki R, Onami S J Toxicol Pathol. 2024; 37(3):133-137.

PMID: 38962259 PMC: 11219191. DOI: 10.1293/tox.2024-0022.


Keeping Pathologists in the Loop and an Adaptive F1-Score Threshold Method for Mitosis Detection in Canine Perivascular Wall Tumours.

Rai T, Morisi A, Bacci B, Bacon N, Dark M, Aboellail T Cancers (Basel). 2024; 16(3).

PMID: 38339394 PMC: 10854568. DOI: 10.3390/cancers16030644.


Cross-species evaluation of fibroblast activation protein alpha as potential imaging target for soft tissue sarcoma: a comparative immunohistochemical study in humans, dogs, and cats.

Beer P, Pauli C, Haberecker M, Grest P, Beebe E, Fuchs D Front Oncol. 2023; 13:1210004.

PMID: 37727209 PMC: 10505752. DOI: 10.3389/fonc.2023.1210004.


Stem cell pathology: histogenesis of malignant fibrous histiocytoma and characterization of myofibroblasts appearing in fibrotic lesions.

Yamate J J Vet Med Sci. 2023; 85(9):895-906.

PMID: 37460298 PMC: 10539815. DOI: 10.1292/jvms.23-0225.


Animal models of Soft Tissue Sarcoma for alternative anticancer therapy studies: characterization of the A-72 Canine Cell Line.

Razzuoli E, Chirullo B, De Ciucis C, Mecocci S, Martini I, Zoccola R Vet Res Commun. 2023; 47(3):1615-1627.

PMID: 37038001 PMC: 10484808. DOI: 10.1007/s11259-023-10115-z.